CT-388 — EU research guide.
CT-388 (also called RO7690479 or enicepatide) is Roche's investigational once-weekly dual GLP-1/GIP receptor agonist for obesity, acquired via the 2023 Carmot Therapeutics buyout.
What is CT-388?
CT-388 activates both the GLP-1 and GIP receptors with minimal β-arrestin recruitment, a design intended to preserve efficacy while limiting receptor desensitisation. It's dosed by weekly subcutaneous injection, in the same mechanism class as tirzepatide.
What does the research show?
Roche's Phase 2 CT388-103 trial (469 adults with obesity, reported January 2026) showed 22.5% placebo-adjusted weight loss at 48 weeks with no plateau; over 95% of patients on the top dose lost at least 5% of body weight. Phase 3 trials ENITH-1 and ENITH-2 began in Q1 2026, alongside a planned combination study with the amylin analogue petrelintide.
EU legal status
Not approved anywhere. CT-388 is an investigational pharmaceutical owned by Roche/Genentech; it has no legitimate research-peptide supply route, and gray-market material claiming to be CT-388 cannot be authenticated.
Molecular information
Pharmacokinetics
Dual-agonist compounds across EU suppliers
COA-verified EU vendors · Updated monthly